Date: 2011-06-06
Type of information: Licensing agreement
Compound: living attenuated vaccines
Company: Cellectis (France) VitamFero (France)
Therapeutic area: Infectious diseases
Type agreement: R&D development licensing
Action mechanism:
Disease: parasite infections
Details: Cellectis and VitamFero have concluded a research, development and licensing partnership agreement. This agreement will grant VitamFero access to Cellectis’ proprietary meganuclease technology for the design and development of a new generation of living attenuated vaccines. Under this 5-year agreement, Cellectis will supply VitamFero with preselected meganucleases for initial use in the development of vaccines against parasites responsible for toxoplasmosis, neosporosis, and others.
Financial terms: Financial details were not disclosed.
Latest news:
